Cyclacel Pharmaceuticals Stock

Cyclacel Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The company is working to develop innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The company is a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival.

The company’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. The company has retained rights to commercialize its clinical development candidates and its business objective is to enter into selective partnership arrangements with these programs. Substantially all the company’s efforts to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.

The company’s pipeline of innovative medicines aims to provide safe and effective anticancer treatment options to patients combined with the convenience of oral administration. The company’s active and planned Phase 1/2 clinical studies use of oral administration as empirical data from its clinical studies suggests that daily dosing by the oral route is a preferred strategy for both its drugs. The company also conducted certain early clinical studies using i.v. administration.

The company retains all global marketing rights to the compounds associated with its clinical-stage drug programs.

The company completed enrollment in a Phase 1 study evaluating i.v. fadraciclib in combination with venetoclax in patients with relapsed or refractory AML or MDS. In its Polo-like Kinase, or PLK, inhibitor program, the company has discovered potent and selective small molecule inhibitors of PLK1. The company has retained worldwide rights to commercialize plogosertib.

Business Strategy

The company’s plan to continue to build a diversified biopharmaceutical business focused on hematology and oncology based on a pipeline of novel drug candidates and utilizing its area of historical expertise in cancer cell cycle and mitosis biological mechanisms. The company’s clinical development strategy focuses on two ongoing programs in transcriptional regulation and mitosis control biology.

The key elements of the company’s strategy are to focus on the cell cycle and cancer; develop anticancer drug candidates in all phases of the cell cycle and multiple compounds for particular cell cycle targets; and enter into partnering arrangements selectively, while developing its own sales and marketing capability.

Licenses

Some of the company’s programs are based on technology licensed from others. The company’s breach of an existing license or failure to obtain a license to technology required to develop, test and commercialize its products may seriously harm its business.

Patents and Proprietary Technology

Patents and Proprietary Rights

The company owns 16 patents granted in the United States, 8 granted by the European Patent Office, or EPO, and 46 granted in other countries worldwide. In addition, the company has a license to 15 patents granted in the U.S., by the EPO or worldwide.

The company has 3 patent applications pending in the United States, 4 before the EPO and 30 pending patent applications in other countries.

Research and Development

The company research and development expenses included $20.3 million for the year ended December 31, 2022.

History

Cyclacel Pharmaceuticals, Inc. was founded in 1996.